Row with Cipla over cancer drug not PIL: Roche

Row with Cipla over cancer drug not PIL: Roche
Comment E-mail Print Share
First Published: Fri, Aug 01 2008. 07 17 PM IST
Updated: Fri, Aug 01 2008. 07 17 PM IST
New Delhi: Legal counsel for Swiss drug maker F. Hoffman-La Roche Ltd on Friday, while arguing before the Delhi High Court for an order restraining rival Indian company Cipla Ltd from selling cheaper copies of cancer drug Tarceva, said that it was a ’bilateral’ lawsuit between companies and not a ’public interest litigation’ where the overriding consideration would be the larger public health.
Roche has filed for an injunction earlier before a single judge bench in HC, saying Tarceva is a patented drug and hence, Cipla’s cheaper copies infringed its patent -- a plea that was turned down as it would have denied patients a medicine that costs a third of the patented version.
”Their (Cipla’s) whole argument is I’m better because I’m cheaper,” Roche’s lawyer, Abhishek M Singhvi said in court, adding that Roche was already giving Tarceva free of cost to patients who were referred to them by the doctors, as part of its ”patient assistance programmes”.
Cipla’s counsel Arun Jaitley will be putting up his arguments in favour of the denial of injunction on 7 August before the two member HC bench consisting of the Chief Justice Ajit Prakash Shah and Justice S Muralidhar.
Comment E-mail Print Share
First Published: Fri, Aug 01 2008. 07 17 PM IST
More Topics: Roche | Cipla | Pharmaceutical | Litigation | Cancer |